ACT017

ACT017 is a Fab fragment of humanized anti-GPVI monoclonal antibody. ACT017 inhibits collagen-induced platelet aggregation. ACT017 has the potential for the research of acute ischemic stroke[1][2].

Product Specifications

CAS Number

[2101829-58-5]

UNSPSC

12352203

Target

Glycoprotein VI

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/glenzocimab.html

Purity

99.00

Solubility

10 mM in DMSO

Smiles

[ACT017]

Molecular Weight

(48.29 kDa)

References & Citations

[1]Wichaiyo S, et al. Glenzocimab: A GPVI (Glycoprotein VI) -Targeted Potential Antiplatelet Agent for the Treatment of Acute Ischemic Stroke. Stroke. 2022 Nov;53 (11) :3506-3513. |[2]Lebozec K, et al. Design, development and characterization of ACT017, a humanized Fab that blocks platelet's glycoprotein VI function without causing bleeding risks. MAbs. 2017 Aug/Sep;9 (6) :945-958.